NO990059L - Analoger av kationiske proteiner - Google Patents

Analoger av kationiske proteiner

Info

Publication number
NO990059L
NO990059L NO990059A NO990059A NO990059L NO 990059 L NO990059 L NO 990059L NO 990059 A NO990059 A NO 990059A NO 990059 A NO990059 A NO 990059A NO 990059 L NO990059 L NO 990059L
Authority
NO
Norway
Prior art keywords
analogs
cationic proteins
cationic
proteins
Prior art date
Application number
NO990059A
Other languages
English (en)
Norwegian (no)
Other versions
NO990059D0 (no
Inventor
Thomas C Boone
Ellen Ngoi Yin Cheung
Susan Irene Hershenson
John David Young
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO990059D0 publication Critical patent/NO990059D0/no
Publication of NO990059L publication Critical patent/NO990059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO990059A 1996-07-19 1999-01-07 Analoger av kationiske proteiner NO990059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68435396A 1996-07-19 1996-07-19
PCT/US1997/012609 WO1998003546A1 (en) 1996-07-19 1997-07-17 Analogs of cationic proteins

Publications (2)

Publication Number Publication Date
NO990059D0 NO990059D0 (no) 1999-01-07
NO990059L true NO990059L (no) 1999-03-19

Family

ID=24747700

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990059A NO990059L (no) 1996-07-19 1999-01-07 Analoger av kationiske proteiner

Country Status (11)

Country Link
US (4) US6211150B1 (de)
EP (1) EP0938499A1 (de)
AU (1) AU720232B2 (de)
CA (1) CA2259163C (de)
CZ (1) CZ399A3 (de)
IL (1) IL127872A0 (de)
NO (1) NO990059L (de)
NZ (1) NZ333650A (de)
SK (1) SK1499A3 (de)
WO (1) WO1998003546A1 (de)
ZA (1) ZA976326B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284143A1 (de) * 2001-08-17 2003-02-19 Sifi S.p.A Verfahren zur Herstellung von pharmazeutischen Lactoferrin enthaltenden Formulierungen
BRPI0408501A (pt) 2003-03-19 2006-03-14 Biogen Idec Inc proteìna de ligação ao receptor nogo
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP1720564A1 (de) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht oder diabetes mit nt-4/5
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
US7476331B2 (en) * 2005-02-09 2009-01-13 E I Du Pont Nemours And Company Compositions comprising 1,1,1,2,2,3,4,5,5,6,6,7,7,7-tetradecafluoroheptane and uses thereof
EP3050963B1 (de) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
CA2610771A1 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2007058843A2 (en) * 2005-11-15 2007-05-24 Lentigen Corporation Web based vector design
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
AU2007232873B2 (en) * 2006-03-31 2014-02-20 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) * 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102339457B1 (ko) 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
RU2010116756A (ru) * 2007-09-28 2011-11-10 Чугаи Сейяку Кабусики Кайся (Jp) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
SI2275443T1 (sl) 2008-04-11 2016-03-31 Chugai Seiyaku Kabushiki Kaisha Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TW201041595A (en) 2009-05-15 2010-12-01 Chugai Pharmaceutical Co Ltd Anti-axl antibody
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP3143404B1 (de) 2014-05-16 2018-08-29 Amgen Inc. Verfahren zur bestimmung von th1- und th2- zellpopulationen
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3981794A1 (de) 2014-12-19 2022-04-13 Chugai Seiyaku Kabushiki Kaisha Anti-c5-antikörper und verfahren zur verwendung
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
MX2017010858A (es) 2015-02-27 2017-12-11 Chugai Pharmaceutical Co Ltd Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN108699160A (zh) 2015-07-28 2018-10-23 奥德纳米有限公司 用于治疗耳部病况的TrkB或TrkC激动剂组合物和方法
JP6923509B2 (ja) 2015-07-28 2021-08-18 オトノミ—，インク． 切断型のｔｒｋｂおよびｔｒｋｃのアンタゴニストを使用する処置
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
US20200131518A1 (en) 2017-03-14 2020-04-30 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3197930A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6247647B1 (en) * 1988-09-19 2001-06-19 Symbol Technologies, Inc. Scan pattern generator convertible between multiple and single line patterns
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
JPH0595786A (ja) 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
US5349055A (en) 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
EP0668352A1 (de) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein mit TPO-Aktivität
EP0785950B1 (de) * 1994-10-13 2003-04-16 Amgen Inc., Analogen des keratinozytenwachstumfaktors
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy

Also Published As

Publication number Publication date
US6500429B2 (en) 2002-12-31
NO990059D0 (no) 1999-01-07
WO1998003546A1 (en) 1998-01-29
SK1499A3 (en) 1999-08-06
AU3671297A (en) 1998-02-10
US6211150B1 (en) 2001-04-03
NZ333650A (en) 2000-02-28
US20010027179A1 (en) 2001-10-04
ZA976326B (en) 1998-02-03
IL127872A0 (en) 1999-10-28
EP0938499A1 (de) 1999-09-01
AU720232B2 (en) 2000-05-25
CA2259163C (en) 2004-07-06
CA2259163A1 (en) 1998-01-29
US20050143294A1 (en) 2005-06-30
US6723701B2 (en) 2004-04-20
CZ399A3 (cs) 1999-06-16
US20020010135A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
NO990059D0 (no) Analoger av kationiske proteiner
NO986202D0 (no) FremgangsmÕte for fremstilling av rekombinant adÚnovirus
PT892640E (pt) Composicoes farmaceuticas de micofenolato entericamente revestidas
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
NO993068L (no) Ny forbindelsesform
DE69725205D1 (de) Befestigung von Biomolekülen
DE69718393D1 (de) Befestigung von Biomolekülen
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
NO995134L (no) Forbedrede fremgangsmåter for fremstilling av aktivert protein C
EE200000365A (et) Bispidiini uued arütmiavastased ühendid
BR9611130A (pt) Derivados de 3-aril-5-halógeno-pirona
DE69518743D1 (de) Modifizierung von nukleotidanalogen
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
ID16838A (id) Komposisi dekafluoropentana
BR9607046A (pt) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas
DE69733607D1 (de) Herstellung von cycloalkyldiarylphosphinen
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69710305D1 (de) Derivate von 4-Vinyl-4'-alpha-hydroxyethyl-biphenyl
DE69811256D1 (de) Polymorphe modifikationen von dofetilid
ID17419A (id) Komposisi dekafluoropentana
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
NO991148D0 (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
BR9704770A (pt) Derivados de 1-carba-(detia)-cefalosporina
IT1283641B1 (it) Procedimento per la preparazione di cefalosporine